Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLD1 | P28340 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 14/20 | 0.39 |
| ▸ | POLG | P54098 | 2/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879425 | 1.00 | POLA1 (0.41) | POLA1POLBPOLD1P2RY2POLG | |
| SCHEMBL18879958 | 0.88 | POLA1 (0.40) | POLA1POLBPOLD1P2RY2POLG | |
| SCHEMBL19590285 | 0.78 | POLB (0.43) | POLA1POLBPOLD1P2RY2POLG | |
| SCHEMBL22765926 | 0.78 | TK1 (0.36) | — | |
| SCHEMBL24858818 | 0.77 | POLA1 (0.40) | POLA1POLBPOLD1P2RY2POLG | |
| SCHEMBL22110712 | 0.74 | POLB (0.55) | POLA1POLBPOLD1P2RY2POLG | |
| SCHEMBL7906710 | 0.74 | POLB (0.55) | POLA1POLBPOLD1P2RY2POLG | |
| SCHEMBL7906708 | 0.74 | POLB (0.55) | POLA1POLBPOLD1P2RY2POLG | |
| SCHEMBL22110865 | 0.74 | P2RY2 (0.61) | POLA1P2RY2P2RY4P2RY6 | |
| SCHEMBL1501001 | 0.74 | P2RY2 (0.61) | POLA1P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301346-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301346-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | POLA1 171/4885POLB 28/4885POLD1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.